Pretzel advances mitochondrial therapy with PX578 Phase 1 trial

[Boscoejean]

Treatment designed to boost mitochondrial function-- New Zealand

parkinsonsnewstoday.com/new...

Pretzel Therapeutics has launched a Phase 1 clinical trial to study PX578, a therapy designed to boost the function of mitochondria, the cell’s energy-producing powerhouses, and address conditions caused by faulty energy production. These include rare genetic conditions and neurodegenerative disorders like Parkinson’s and Alzheimer’s.

The Phase 1 study (ACTRN12625000230459p) will evaluate PX578’s safety and tolerability, as well as how the compound is processed in the body, by administering single and multiple increasing oral doses to healthy volunteers. Patient enrollment is expected to begin by the end of the month, and the trial aims to recruit up to 112 participants in New Zealand.